Futures are pointing to a rebound at the Friday Wall Street open ahead of the long holiday weekend, but not nearly enough to make up for the week's losses.Morning Briefread more
May had failed to win a parliamentary majority on Britain's withdrawal from the European Union.Europe Politicsread more
"We have a high degree of confidence that AMZN shares can reach this level with no major acquisitions or other significant changes to the business."Investingread more
Investors are rushing into the relative safe haven of the bond market, causing the yield on the U.S. 10-year Treasury to plummet.Real Estateread more
China denounced U.S. Secretary of State Mike Pompeo for fabricating rumors after he said the chief executive of China's Huawei was lying about his company's ties to the...World Politicsread more
U.S. President Donald Trump on Thursday predicted a swift end to the ongoing trade war with China, although no high-level talks have been scheduled between the two countries.World Economyread more
A downgrade from BMO analysts led to an unsavory drop in Chipotle's stock, and some analysts are advising waiting out the weakness.Trading Nationread more
President Donald Trump has threatened tariffs on another $300 billion worth of Chinese goods — but Chinese PC-maker Lenovo is prepared to shift its production if that happens,...Technologyread more
Indian Prime Minister Narendra Modi won a landslide re-election victory. That could see India taking a more assertive security stance.Asia Politicsread more
The Wall Street Journal and The New York Times, citing people familiar with the deal, reported that $30 million would go to plaintiffs and $14 million would be used to pay...Entertainmentread more
Danish shipping group A.P. Moller-Maersk on Friday posted first-quarter profit close to expectations and warned that trade tensions and slowing economic growth constitute...Earningsread more
SAN DIEGO, May 12, 2015 (GLOBE NEWSWIRE) -- Genelux Corporation, a clinical-stage biopharmaceutical company focused on the development of vaccinia virus for oncolytic immunotherapy, today announced that two posters supporting the ongoing clinical development of its lead clinical candidate GL-ONC1 will be presented at the upcoming 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29-June 2 in Chicago, IL.
Lead investigators from Memorial Sloan Kettering Cancer Center and UC San Diego Moores Cancer Center will present findings from two separate Phase I clinical trials evaluating GL-ONC1 in the treatment of head and neck cancer and malignant pleural effusion, a condition in which fluid builds up between the tissues that line the lungs and the chest.
"Nearly 90 patients with various tumor types have been dosed with GL-ONC1 in four clinical trials to date, demonstrating a favorable safety profile and evidence of anti-tumor activity," commented Thomas Zindrick, President & CEO of Genelux Corporation. "Following the recent FDA panel meeting that ruled in favor of Amgen's herpes virus for treatment of malignant melanoma, increased attention is being placed on oncolytic immunotherapies. We look forward to sharing results of our two Phase I trials separately evaluating GL-ONC1 in head and neck and mesothelioma/lung cancers with the global oncology community at ASCO and further validating this cancer therapy as a promising treatment modality. We believe GL-ONC1 has the potential to effectively treat a range of cancers by precisely selecting and destroying cancer cells without harming healthy tissues or organs and by awakening the immune system for long-term immunotherapy."
Details of the two abstracts accepted for poster presentation are outlined below:
|-- Abstract 6026 / Poster 349: Phase I trial of intravenous attenuated vaccinia virus (GL-ONC1) with concurrent chemoradiotherapy (CRT) for locoregionally advanced head and neck carcinoma.|
|First / Presenting Author:||Loren K. Mell, M.D., UC San Diego Moores Cancer Center|
|Poster Session:||Head and Neck Cancer|
|Date, Time:||Saturday, May 30; 1:15 PM - 4:45 PM|
|Location:||S Hall A, McCormick Place|
|-- Abstract 7559 / Poster 307: Phase I study of intra-pleural administration of GL-ONC1, an oncolytic vaccinia virus, in patients with malignant pleural effusion.|
|First / Presenting Author:||Lee M. Krug, MD, Memorial Sloan Kettering Cancer Center|
|Poster Session:||Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers|
|Date, Time:||Monday, June 1; 8:00 - 11:30 AM|
|Location:||S Hall A, McCormick Place|
GL-ONC1, the company's lead oncology product candidate, is an attenuated vaccinia virus (Lister strain). Vaccinia virus, a non-pathogenic virus, was used safely in millions of people as the vaccine against smallpox. Scientists at Genelux have modified this virus to increase its safety, tumor selectivity and anti-tumor activity without limiting its ability to replicate in and kill cancer cells. Such virus-mediated oncolysis triggers immune activation, for long-term immunotherapy against cancer. GL-ONC1 is currently under evaluation in multiple Phase 1 and 1/2 clinical trials in the US and Europe. Clinical results have shown GL-ONC1 is well tolerated with minimal toxicity and exhibits evidence of anti-tumor activity.
About Genelux Corporation
Headquartered in San Diego, California, Genelux Corporation is a privately-held, clinical-stage biopharmaceutical company dedicated to fundamentally changing the way in which cancer is diagnosed and treated. The company has developed a proprietary, vaccinia virus-based technology platform. Such platform can also be engineered to insert specific genes for delivery and amplification of therapeutic and diagnostic proteins. For more information please visit www.genelux.com.